Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CASTLE: Carbamazepine, Levetiracetam or Active Monitoring With or Without Sleep Intervention in Rolandic Epilepsy
NCT04610879Phase 4Terminated
- Sponsor
- King's College London
- Start
- Aug 2019
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of levetiracetam and carbamazepine in Benign Rolandic Epilepsy (BECTS) (6 arms), sponsored by King's College London. Primary endpoints: Time to 6-month seizure remission and Children's Sleep Habits Questionnaire at 3 months. Started Aug 2019; status: terminated.
02
Drugs
levetiracetamcarbamazepine
03
Conditions
Benign Rolandic Epilepsy (BECTS)
Beyond the preview
Go deeper on NCT04610879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04610879.